Li-Ping Sun
Molecular Biology · 2023
A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 78 citations into it
- Cancer Research — 43 citations into it
- Genetics — 6 citations into it
- Hematology — 5 citations into it
Whom Li-Ping Sun trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Li-Ping Sun's perspective
Ordered by how strongly the researchers Li-Ping Sun trusts endorse each paper. Same corpus, a different order for every researcher.
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (Cancer Cell)
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
- Molecular mechanisms and clinical applications of angiogenesis (Nature)
- Targeting HIF-1 for cancer therapy (Nature Reviews. Cancer)
- Basic and therapeutic aspects of angiogenesis. (Cell)
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy (Science)
- Opinion: Angiogenesis: an organizing principle for drug discovery? (Nature reviews. Drug discovery)
- New functions for the matrix metalloproteinases in cancer progression (Nature Reviews. Cancer)
- Sorafenib in advanced clear-cell renal-cell carcinoma. (New England Journal of Medicine)
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (Cancer Research)
Their papers
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023) — 1,151 citations